The L&D Code Cart Is Empty
The Signal - Obstetric medication shortages · rolling stockouts · the drugs that keep women alive
Thesis #3 — You cannot run a hemorrhage protocol on a medication that is not in the building.
🗂️ This Week’s Evidence
In the clinical environment of labor and delivery, time is the ultimate currency. Obstetric emergencies — postpartum hemorrhage, eclamptic seizures, uterine rupture — can escalate from stable to fatal in minutes. The bedrock of managing these crises is immediate access to a highly specific, non-interchangeable armamentarium of essential medications.
That armamentarium is disappearing.
The FDA’s national Drug Shortages list doesn’t classify misoprostol or magnesium sulfate as in active nationwide critical shortage — despite documented manufacturer-specific back orders (Fresenius Kabi’s magnesium sulfate 40 mg/mL bags on back order through mid-2026). What’s happening on the ground is an acute local access and allocation crisis.
ASHP tracked 223 active drug shortage cases in Q1 2026. Drug shortages are trending upward.
📋 The Core Obstetric Formulary
The drugs that keep women alive during childbirth are generic, off-patent, and cost almost nothing to produce:
Oxytocin — first-line uterotonic for postpartum hemorrhage
Misoprostol — cervical ripening, miscarriage management, hemorrhage treatment
Magnesium sulfate — gold standard for preventing eclamptic seizures
Methylergonovine and carboprost — second-line uterotonics
Tranexamic acid — antifibrinolytic for massive hemorrhage
These cost pennies per dose. Their absence from hospital shelves is not an economic problem. It is a political one.
⚙️ The Mechanism
The generic sterile injectable market is heavily consolidated, operating on razor-thin profit margins. When one of the few remaining manufacturers has a production delay or fails an FDA inspection, the supply chain fractures. Distributors deploy allocation algorithms that leave rural and safety-net hospitals without adequate safety stock.
Misoprostol is uniquely compounded by politics. Although the drug itself remains broadly stocked at retail chains, it has been swept into the chilling effect surrounding medication-abortion regulation — pharmacists refusing dispensing for routine obstetric indications, hospital restocking delayed by legal-liability concerns.
🩺 From the Bedside
Postpartum hemorrhage. The protocol is algorithmic — oxytocin first, then misoprostol, then second-line agents if needed. Except when the pharmacy is on allocation. Except when misoprostol supply is restricted because of political pressure on the distributor. Except when the backup — methylergonovine — is contraindicated because the patient has preeclampsia.
So now I’m running a hemorrhage protocol with half the drugs. I’m making substitution decisions in real time while a patient is actively bleeding. This is not clinical judgment. This is triage forced by a supply chain that has been politically and structurally compromised.
— Dr. Yamicia Connor, OB/GYN
The series so far
Week 1 · Title X
🗂️ Title X Is Being Dissolved Without a Vote — The Signal
📋 What the Lawyers Know — The Briefing
🩺 The Tubal She Chose — Viva Voce
Week 2 · PRAMS
🗂️ No One Signed the Death Certificate — The Signal
📋 Why They Came for PRAMS — The Briefing
🩺 The Watching Is the Care — Viva Voce
Coming this week — Week 3 · Medication Shortages:
Thursday — The Briefing: the specific market failures, the regulatory gaps that allow rolling stockouts to persist, and the policy interventions that could restore supply chain resilience.
Friday — Viva Voce: from the exam room: when the medicine has limits, and the supply chain has been politicized.
Read the full series:
✊🏽 WHY SUBSCRIBE
You can read me anywhere. There are louder takes. There are faster newsfeeds. There are bigger names. What you get here that you don’t get anywhere else is THE SPINE — a permanent argumentative scaffold you can stand on, walk along, share with the people you’re trying to convince, and keep coming back to over years.
The reason your premium went up $1,000. The reason your sister’s cancer trial got pulled. The reason Pap smears are disappearing from rural counties.
THEY ARE THE SAME REASON.
That’s the case we’re making, week after week, until the country can see it.
Thank you for being here. Forward this to one person who needs the spine.
— YC
Dr. Yamicia Connor, MD, PhD, MPH
Founder & CEO, Diosa Ara | Creator & Editor-in-Chief, The Labora Collective
